BRD4 and lung cancer: Characterization confirmed the nanoparticles’ stability, high drug-loading capacity, and triggerable drug release under acidic and reducing conditions, resulting in enhanced BRD4 degradation, caspase-3 activation, and apoptosis in lung cancer cells.